Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…
McAlinden Research PartnersMay 25, 2023
Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…
McAlinden Research PartnersOctober 19, 2022
The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…
McAlinden Research PartnersSeptember 29, 2022
A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…
McAlinden Research PartnersJuly 11, 2022
